For example, pain outcomes may not be applicable to agents that reduce hemolysis (Gardos channel inhibitors) or target NO signaling, since they may be more likely to be beneficial in the vasculopathy subphenotype (pulmonary hypertension, priapism). Here, KCNN4 is linked to Priapism.